TABLE 1.
Patient and treatment characteristics associated with occlusion of peripherally inserted central catheters
| Characteristic | No. (%) or median (IQR) |
Multivariable logistic regression analysis |
||||
|---|---|---|---|---|---|---|
| Total (n = 285) | Bivariate analysis |
|||||
| No occlusion (n = 206) | Occlusion (n = 79) | P value | Adjusted odds ratio (95% CI) | P value | ||
| Age (yrs) | 65 (51–73) | 66 (51–74) | 63 (52–71) | 0.44 | 1.01 (0.98–1.03) | 0.64 |
| Sex | ||||||
| Male | 170 (59.6) | 129 (62.6) | 41 (51.9) | Reference | 0.42 (0.20–0.90) | 0.03 |
| Female | 115 (40.4) | 77 (37.4) | 38 (48.1) | 0.13 | ||
| Current tobacco use | 52 (18.2) | 35 (17.0) | 17 (21.5) | 0.48 | 2.03 (0.80–5.17) | 0.14 |
| Active malignancy | 42 (14.7) | 30 (14.6) | 12 (15.2) | 1.00 | 1.07 (0.42–2.73) | 0.88 |
| Diabetes | 89 (31.2) | 63 (30.6) | 26 (32.9) | 0.81 | 1.09 (0.48–2.49) | 0.83 |
| Obesity | 54 (18.9) | 36 (17.5) | 18 (22.8) | 0.39 | 1.21 (0.49–3.02) | 0.68 |
| VTEa history | 15 (5.3) | 13 (6.3) | 2 (2.5) | 0.25 | 0.39 (0.07–2.10) | 0.14 |
| PICCb site of insertion | ||||||
| Right | 40 (14.0) | 27 (13.1) | 13 (16.5) | Reference | 1.78 (0.68–4.75) | 0.24 |
| Left | 245 (86.0) | 179 (86.9) | 66 (83.5) | 0.59 | ||
| No. of lumina for PICC | ||||||
| 1 | 171 (60.0) | 149 (72.3) | 22 (27.8) | Reference | ||
| 2 | 114 (40.0) | 57 (27.7) | 57 (72.2) | <0.001 | 11.33 (5.45–24.25) | <0.0001 |
| Antibiotic duration (wks) | 5.4 (4.0–6.1) | 5.3 (3.6–6.1) | 5.7 (4.9–6.4) | 0.01 | 1.25 (1.06–1.47) | 0.009 |
| No. of antibiotics | ||||||
| 1 | 247 (86.7) | 181 (87.9) | 66 (83.5) | Reference | ||
| 2 | 38 (13.3) | 25 (12.1) | 13 (16.5) | 0.44 | ||
| Antibiotic | ||||||
| Ampicillin | 11 (3.9) | 10 (4.9) | 1 (1.3) | 0.30 | 0.13 (0.01–1.39) | 0.09 |
| Cefazolin | 64 (22.5) | 56 (27.2) | 8 (10.1) | 0.001 | 0.47 (0.11–2.00) | 0.31 |
| Ceftazidime | 9 (3.2) | 8 (3.9) | 1 (1.3) | 0.45 | 0.12 (0.01–1.51) | 0.10 |
| Ceftriaxone | 64 (22.5) | 52 (25.2) | 12 (15.2) | 0.08 | 0.64 (0.18–2.19) | 0.47 |
| Cloxacillin | 18 (6.3) | 9 (4.4) | 9 (11.4) | 0.05 | 5.91 (1.04–33.64) | 0.045 |
| Ertapenem | 19 (6.7) | 10 (4.9) | 9 (11.4) | 0.06 | 1.00 (0.22–4.57) | 1.00 |
| Meropenem | 9 (3.2) | 7 (3.4) | 2 (2.5) | 1.00 | 0.33 (0.04–2.73) | 0.31 |
| Penicillin G | 18 (6.3) | 7 (3.4) | 11 (13.9) | 0.002 | 11.55 (2.10–63.38) | 0.005 |
| Piperacillin-tazobactam | 45 (15.8) | 30 (14.6) | 15 (19.0) | 0.37 | 1.74 (0.41–7.45) | 0.46 |
| Vancomycin | 71 (24.9) | 46 (22.3) | 25 (31.6) | 0.13 | 1.75 (0.62–4.97) | 0.29 |
a
VTE, venous thromboembolism.
b
PICC, peripherally inserted central catheter.